BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.82 USD
+0.01 (1.26%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.82 0.00 (-0.07%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
BioLineRx Ltd. [BLRX]
Reports for Purchase
Showing records 121 - 140 ( 205 total )
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
PRESERVATION - Data Soon; Should Serve as Proxy for Upcoming U.S. Study
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Previewing PRESERVATION-1 Topline Data; EHA ''8040 Updates; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q15 Results; Two Major Data Catalysts in 2015 for ''1040 and ''8040
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
BL-8040 Continues Its Push Forward; BL-1004 Data Soon; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Healthcare: Shaky Sector; Focus on Defined Catalysts for Remainder of 2015
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Positive SC Mobilization Topline Data Positions ''8040 as Alternate to SOC
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2014 Results; Expecting 2015 Milestones From Three Lead Programs
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Healthcare Recap: Opportunities and Catalyst Focus Name of Game Going Forward
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Teeing Up Another Major Catalyst This Year; BL-1040 Data; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
BL-8040 Stem Cell Mobilization Study Wraps Part I; Topline Data In 1Q15
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Additional Business Development Activity with Licensing Out Of BL-5010
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J